Cite
HARVARD Citation
Forman, M. et al. (2019). Safety, Tolerability, and Pharmacokinetics of the β‐Site Amyloid Precursor Protein‐Cleaving Enzyme 1 Inhibitor Verubecestat (MK‐8931) in Healthy Elderly Male and Female Subjects. Clinical and translational science. 12 (5), pp. 545-555. [Online].